SomnoMed Limited (SOMNF)
OTCMKTS
· Delayed Price · Currency is USD
0.3852
-0.0162 (-4.04%)
At close: Mar 20, 2025
SomnoMed Revenue
SomnoMed had revenue of 53.71M AUD in the half year ending December 31, 2024, with 34.40% growth. This brings the company's revenue in the last twelve months to 100.25M, up 12.93% year-over-year. In the fiscal year ending June 30, 2024, SomnoMed had annual revenue of 91.65M with 9.61% growth.
Revenue (ttm)
100.25M AUD
Revenue Growth
+12.93%
P/S Ratio
0.94
Revenue / Employee
334.15K AUD
Employees
300
Market Cap
58.06M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 91.65M | 8.03M | 9.61% |
Jun 30, 2023 | 83.62M | 11.04M | 15.20% |
Jun 30, 2022 | 72.58M | 9.87M | 15.75% |
Jun 30, 2021 | 62.71M | 5.41M | 9.44% |
Jun 30, 2020 | 57.30M | -1.60M | -2.71% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |